Protara Therapeutics, Inc. Common Stock (TARA) Stock Price
TARAStock
$3.97+24.44%52W
Market Cap$234.61M
P/E—
PEG Ratio—
Div yield—
Beta1.46
TARA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-53.23%
Price vs S&P 500 (4W)-4.83%
VGM Score36.49
TARA Earnings Surprise History
Q2 25-0.35est. -0.41
Q3 25-0.31est. -0.39
Q4 25-0.38est. -0.31
Q1 26-0.31est. -0.37
Q2 26-0.36est. -0.31
TARA Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.14
4.14
4.14
4.14
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TARAProtara Therapeutics, Inc. Common Stock | — | — | D | $3.97 |
| AMGNAmgen Inc | C | C | B | $442.24 |
| GILDGilead Sciences Inc | C | B | B | $148.77 |
| MRNAModerna, Inc. Common Stock | D | C | A | $158.83 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1019.49 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $211.38 |
| BIIBBiogen Inc. Common Stock | C | D | B | $220.77 |
| BNTXBioNTech SE American Depositary Share | C | C | B | $114.05 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $153.37 |
| EXELExelixis Inc | C | B | B | $56.72 |
| HALOHalozyme Therapeutics, Inc. | C | B | A | $109.32 |
About Protara Therapeutics, Inc. Common Stock
Protara Therapeutics develops transformative therapies for cancer and rare diseases with limited treatment options. The pipeline includes TARA-002 for lymphatic malformations and intravenous choline chloride for intestinal failure-associated liver disease (IFALD). The company focuses on underserved patient populations with significant unmet medical needs.